Vivus, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (47)

Latest Posts

About This Stock More About This Stock
Stock Charts To Watch - Tuesday, March 31
Article By: Harry Boxer
Tuesday, March 31, 2020 9:24 PM EDT
Akero Therapeutics, Inc. had a big pop premarket Tuesday morning, then came down when the market opened, and consolidated, before finishing up 4.02, or 23.4%, to 21.20, reached a high of 22.39, on 1.6 million shares traded.
In this article: CNQ, GVA, AKRO, MX, SGBX, VVUS
Read
3 Biotech Stocks Up In The Past Month On Industry Turnaround
Article By: Zacks Investment Research
Tuesday, June 5, 2018 1:08 PM EDT
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
In this article: BMRN, LGND, VVUS Also: JNJ
Read
Qualcomm, Inc., VIVUS, Inc. Beat Earnings Estimates
Article By: ValueWalk
Wednesday, November 4, 2015 5:43 PM EDT
Qualcomm reported adjusted earnings of 91 cents per share or $1.4 billion and $5.5 billion in revenue for its fourth fiscal quarter. Vivus posted losses of 15 cents per share and $24.9 million in revenues.
In this article: VVUS, QCOM
Read
Shares Of Orexigen Soar After It Announces Improved Safety Results For Weight-Loss Drug
Article By: Terry Chrisomalis
Tuesday, March 3, 2015 2:37 PM EDT
Orexigen's drug Contrave shows not only shows great safety but also shows the ability to reduce heart-related problems as compared to placebo.
In this article: OREX, ARNA, VVUS
Read
VIVUS Q4 Loss Wider Than Expected, Qsymia Disappoints
Article By: Zacks Investment Research
Wednesday, February 25, 2015 11:56 AM EDT
VIVUS Inc.’s fourth-quarter 2014 loss of 25 cents per share was wider than the Zacks Consensus Estimate loss by a penny and the year-ago loss of 9 cents.
In this article: VVUS
Read

Latest Tweets for $VVUS

No tweets yet!

PARTNER HEADLINES